Health Care & Life Sciences » Pharmaceuticals | Tetraphase Pharmaceuticals Inc.

Tetraphase Pharmaceuticals Inc. | Ownership

Companies that own Tetraphase Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
BlackRock Fund Advisors
3,906,332
7.39%
138,421
0%
06/30/2018
The Vanguard Group, Inc.
2,238,778
4.24%
109,503
0%
06/30/2018
Dimensional Fund Advisors LP
2,200,413
4.16%
367,672
0%
06/30/2018
SSgA Funds Management, Inc.
1,155,590
2.19%
27,009
0%
06/30/2018
Northern Trust Investments, Inc.
1,064,177
2%
39,476
0%
06/30/2018
Baker Bros. Advisors LP
935,000
1.77%
0
0.02%
06/30/2018
Tekla Capital Management LLC
859,322
1.63%
0
0.1%
06/30/2018
Numeric Investors LLC
737,715
1.4%
-936,626
0.02%
06/30/2018
PanAgora Asset Management, Inc.
729,850
1.38%
170,959
0.01%
06/30/2018
Renaissance Technologies LLC
623,885
1.18%
-328,300
0%
06/30/2018

About Tetraphase Pharmaceuticals

View Profile
Address
480 Arsenal Street
Watertown Massachusetts 02472
United States
Employees -
Website http://www.tphase.com
Updated 07/08/2019
Tetraphase Pharmaceuticals, Inc. engages in the development and production of novel antibiotics for serious and life-threatening bacterial infections. It is currently developing a product candidate, eravacycline, a fully synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Watertown, MA.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.